FDA Advisory Committee Votes in Favor of Earlier Use of Phosphate Binders in Stage 4 Kidney Disease Patients With ... (CNW Group via Yahoo! Finance)

At the U.S. Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee meeting today, the majority of members voted to recommend the use of phosphate binders, including Shire Pharmaceuticals' non-calcium FOSRENOL , to treat hyperphosphatemia in chronic kidney disease Stage 4 patients.

Read More...

[Source: Yahoo! News Search Results for liver disease help]